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The highlights from the workshop presented in this document represent a summary of some of the 
considerations discussed at the workshop. Participants were not asked to endorse the content of this report. The 
responsibility for the final content of this report rests with the International Risk Governance Council. 
  
28-29 August 2015 IRGC workshop highlights – precision medicine risk governance 
4 
 
Background 
Precision medicine is an emerging field for disease diagnostic, prevention and treatment, which takes into 
account individual variability in genes, environment and lifestyle. The sequencing and analysis of individual 
genomes will become a commodity, paving the way to precision (data-driven) medicine to become a major 
industry in the future, particularly as the health-maintenance industry increasingly engages in an anti-aging 
agenda. Precision medicine can identify predisposing genes and risk factors (diagnostic), tailor prevention 
program (life style, nutrition, drugs), continuously record various bio-parameters by integrated biosensors 
(watches, glasses, contact lenses, clothes…), and ultimately improve therapeutic treatment (curation), including 
gene therapies, and regenerative and reproductive medicine. Expectations for precision medicine are high, and 
industry is embarking massively on this route, together with governmental programmes such as in the US1, 
China2 or the UK3.  
 
Workshop highlights 
On 28-29 August 2015, the School of Public Policy and Management at Tsinghua University, the Program on 
Emerging Technologies at the Massachusetts Institute of Technology (MIT), the Swiss Federal Institute of 
Technology (EPFL), and the International Risk Governance Council (IRGC) organised a workshop on the 
ownership, collection and use of genetic information for precision medicine. The workshop was attended by 
experts from Europe, the US, China, India and Singapore. A list of participants, the agenda and background 
readings can be found in appendix.  
The workshop aimed to identify broad opportunities in the field of medical applications of genetic research, and 
associated challenges ranking from scientific and medical uncertainties to challenges to existing business 
models. Were central in the discussions: issues of data ownership, collection and use, and the need to establish 
and develop trust between industry, regulators, public authorities and patients, including for the purpose of 
sharing relevant and accurate data. 
Gene technologies and their application by industry are developing rapidly, particularly in the US and in China. 
Yet, governance of the new field of genomic for precision medicine is developing more slowly and needs to catch 
up. The rapid developments in science and technology but also in how cultures and values consider questions of 
ethics, privacy and data protection, pose challenges to regulators and policymakers. There is no universal 
understanding of what can be done, what should be allowed, what should be prohibited and what should be 
protected and shared, beyond general principles4.  
Learnings from the development of internet can be useful in that respect. Analogies between both fields include 
that: security issues face the challenge of risk internalization, privacy appears to be an essentially contested 
concept (it is a social construct, a surrogate for other values), and data governance involves both operational 
and legal options. However, internet is de facto a collaborative endeavor, whereas genetic research and 
application to precision medicine is not (yet) a field of collaborative work. Rather, the fragmentation of research 
and industry development is still dominated by questions around issues of Intellectual Property and Patents, and 
often marked by secrecy. This is reinforced by some national (e.g. China) or regional (e.g. EC) regulations that 
prevent or restrict sharing of data with other countries. Considering that improvements in precision medicine 
require very large sets of data of various nature (genetic, health and lifestyle), scientists recommend that 
                                                          
1 The US Precision Medicine Initiative, launched in January 2015 and spearheaded by the National Institutes of Health will 
involve collection of data on genomes, electronic health records, and physiological measurements from 1 million 
participants. Update on implementation plans (September 2015) can be found in the “Precision Medicine Initiative (PMI) 
Working Group Report to the Advisory Committee to the Director, NIH”, available online here: 
http://acd.od.nih.gov/reports/DRAFT-PMI-WG-Report-9-11-2015-508.pdf 
Need to add other US important actors and projects? 
2  Large scale multi-disciplinary research will begin in 2016 in China, to support dedicated policies for precision medicine. It is 
expected that codes of conduct for research trials and involvement of industry will be addressed in these policies.  
3 The UK 10K Genomes initiative (http://www.uk10k.org/)  
4 Such as those of the «Framework for responsible sharing of genomic and health-related data  by the «Global Alliance For 
Genomic And Health» or also the Universal Declaration of Human Genome and Human Rights (UNESCO 1998) 
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governance regimes allow and encourage the constitution of large data banks (biobanks), for which appropriate 
governance regimes need to be developed5. The question for policymakers, regulators and industry should thus 
be: how to make this possible (and even encouraged) while preventing misuse (with the term “misuse” to be 
defined). 
This note highlights some key issues and then provides a quick review of opportunities and benefits, risks and 
uncertainties and governance considerations. 
SCIENTIFIC AND TECHNICAL LANDSCAPE  
Advances in foundational 
technologies 
Applications to health and medicine 
 DNA sequencing – 
Generating genomic data 
 Information technology – 
storing, moving, analysing 
genomic data 
 DNA synthesis – building 
genes 
 Tools and methods – 
combining, editing, 
repurposing genes  
 Drug synthesis – Artimisen, opiates … and novel variants 
on existing drugs 
 Modifying disease vectors – gene drives... mosquitos, 
ticks 
 HUMAN PRECISION MEDICINE  
› 1.0 Target conventional drugs on genetically defined 
treatment groups 
› 2.0 Regenerative medicine – Rejuvenate, replace, 
regenerate damaged tissue 
› 3.1 Somatic cell gene therapy (SCGT) – Non-heritable 
alterations 
› 3.2 Germline gene therapy (GGT) – Heritable 
alterations 
 
 
 
1. Key issues to be addressed in the development of precision 
medicine 
 
 Precision medicine is on its way. It will happen, whatever regulation is put in place to constrain it. It must 
be encouraged for the benefits it can bring to both personal (individual) and public health. There should 
be no conflict between investing in better health with the individual as a target and investing in 
improving global health in the world. To meet this goal, development of precision medicine must be 
“governed”, and the public needs to engage with it.  
 Precision medicine will succeed if the objectives and concerns of all affected and other important actors 
are taken into consideration. What does industry want? What do governments and regulators want? 
What do medical doctors want? What do patients want? At the same time, current innovations in 
precision medicine will most probably cause a paradigm shift in health care and powerful actors will 
emerge and must be identified.  
 The dominant global governance issues in the policy agenda-setting process is not defined by a single 
player but by powerful actors with established objectives and concerns that structure the governance 
debate. For example, the scientific community is currently driven and/or concerned by data access, 
government and society are motivated by data privacy and security, ELSi committees, by ethical issues, 
and government/industry, by economic opportunities. We are now in a critical juncture, and it is 
therefore important to identify the key actors who may take leadership roles and set up the governance 
agenda6. 
 Understanding risks and opportunities and their governance options. We need to identify and share as 
broadly as possible with the public and patients, with policymakers and regulators, and with industry, 
what are the main opportunities and benefits, what are the main risks and uncertainties and what are 
                                                          
5 See large biobanks projects in the US and China mentioned above. For Europe, see the BBMRI-ERIC European-wide biobank 
network http://bbmri-eric.eu/ 
6 See Hanzhi Yu’s presentation, about governance 
28-29 August 2015 IRGC workshop highlights – precision medicine risk governance 
6 
 
the possible governance options for encouraging research and application while mitigating the risks and 
resolving the trade-offs (between opportunities and risks and between risk). Transparency is needed to 
establish trust7, in a field that affect people in their most personal matter. 
 Regulation is the cornerstone in this endeavor. Regulation is needed to balance privacy and sharing, and 
this may vary in different contexts, to account for regional and cultural specificities.8 Work is needed to 
define the scope and specificities of relevant legislations, but with three clear principles. First, 
regulation must be developed at the national level, with disposition for international collaboration. 
Second, it must be co-developed with industry, patients and payers. Third, it must also be flexible to 
allow adaptation to new knowledge and changing values and perceptions, at least until we have 
reached a certain level of assurance and trust. New regulations will have to be developed and deal with 
questions of genetic data ownership, data collection in biobanks, and use of data. 
 Privacy and data protection are central to the creation of trust, to facilitate collaboration between actors 
and between countries. The question of IP remains open, for genomic diagnostic tools in particular. For 
example recent cases in the US may indicate that the legislator is revising its appreciation of the pros 
and cons of IP protection for genomic technologies. 
  
 
2. Opportunities and benefits 
 
Such “smart medicine” will bring the benefit of scientific advances to the right person at the right time. It will 
reduce ineffective treatments and their associated costs, when traditional medicine proceeds by “trials and 
errors”. Performance and cost effectiveness will improve for: 
 diagnostic: to diagnose genetic predisposition and help prediction 
 prevention: to focus monitoring on those individuals that have a reasonable chance of developing 
certain health conditions 
 curation: to target therapies to how each patient will respond to it  
Scientific and technological advancements set the scene for improvements in the development of effective gene 
therapies, which are better targeted than conventional therapies. Regenerative therapies can help face the 
economic challenge that degenerative diseases and aging pose to society. 
These opportunities can be seized if society can favorably regulate biobanking, since precision medicine is based 
on knowledge collected from large data sets, organised in biobanks. As acknowledged by the major US, 
European and Chinese biobank projects, biobanks must include both genomic data, health records (patients’ 
medical data) and other data related to lifestyle and the environment. Medical use of none medical data is one 
regulatory challenge; “blank check” consent for use of tissues from biobank is another uncharted legal and social 
territory, with important cultural differences across countries. 
 
  
                                                          
7 “Public trust is required for the proper functioning of government, and governments must be held to a higher standard for 
the collection and use of personal data than private actors.” Big Data: Seizing Opportunities, Preserving Values, Executive 
Office of the President, US White House, May 2014 
8 For an overview of “How privacy law affects medical and scientific research”, see: 
http://www.genomicslawreport.com/index.php/2015/09/01/how-privacy-law-affects-medical-and-scientific-research/ 
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3. Risks and uncertainties 
 
Those can be related to (a) personal health, (b) conventional public health systems and (c) inappropriate 
regulation. 
(a) Risks to personal health and individuals 
Like for any therapeutic treatments, and as enforced by public health authorities worldwide, treatments from 
precision medicine must be authorized (licensed) on the basis of their safety, efficacy, lack of negative side 
effects and cost efficiency. Personalized medicine will probably cause a change in traditional cohort-based 
clinical trials and shift to adverse-effect monitoring patient by patient (“cohort of one”).  
Other risks include uncertainty about how individuals react physically, emotionally and mentally when they are 
informed about their own personal genomic characteristics. Information and education of medical personnel, 
patients and policymakers alike is much needed. The lack of appropriate education about both genomics and 
personal medicine, and how to communicate to non-experts, is recognized as a major barrier to evidence-based 
decisions. In particular, medical genetic counseling has to include probabilities and risk communication, in order 
to avoid unintended consequences, for example for patients’ relatives. 
Major uncertainties to individual health are related to safety and the uncertainty of long term consequences, 
especially when specific genetic traits may be modified for the purpose of obtaining a better or preferred state 
over certain factors. In the case of germline modification9 (which is legally forbidden in probably all countries, 
but may be explored by some researchers), it is impossible to predict the long term consequences.   
There is a risk that, in countries where regulation and governance are lagging behind the technology, private 
sector companies that have sequencing capacity will sell on the market analyses that are not validated for 
clinical or personal use, yet are authorized by their government. The lack of knowledgeable and powerful panels 
of scientists and clinicians is a risk that must be addressed. In the extreme case, rogue research, industry or even 
governments might try what ethicists would describe as “worst-case scenarios”, where human enhancement is 
manipulated in the pursuit of private objectives, self-interest or even eugenism. 
(b) Risks to public health systems 
Current public health systems are facing “business risks” and will probably have to “adapt or fail”. They are 
somehow affected by public policy declarations that the future is in precision medicine, before having been 
given time to think how their regulations for authorization, licensing and cost reimbursement can be adapted or 
revised. The risk of discrimination in access to health care has to be solved. 
(c) Inappropriate regulation 
The lack of policies and standards, and appropriate ethical legal frameworks is a risk to the development of 
precision medicine. Public health authorities must be aware that, whatever they decide, industry will develop 
precision medicine and sell it to patients in needs. Both a lack of- and too strict regulation may deliberately or 
unintentionally affect negatively patients, industry and society. The risk of over-reaction by a regulatory 
authority must be avoided. Key points in regulation will be: genomic data ownership, data protection for privacy 
purposes and data sharing for research purposes, rules and processes for anonymization. Biobanks are at the 
center of the regulation. 
 
  
                                                          
9 Germline modification involves using genome-editing tools to modify the DNA of human embryos in such a way that the 
new genetic material is always passed to the progeny. 
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4. Governance considerations 
 
The advent of precision medicine creates a fundamental transformation of the paradigm of clinical medicine. 
Because the field is evolving rapidly, the first consideration is the need to fully embrace change (that is: what is 
being done today and what could be done tomorrow), together with the need to balance innovation and risk 
management. 
Beyond that, important questions include: 
(a) How to engage with and educate individual and collective decision makers to make good decisions? 
The lack of scientific literacy of ethics and regulatory committees need to be fulfilled before final decisions are 
made about what is allowed. Education in genomics and precision medicine will help people get a sound 
understanding of the science, to differentiate what is hype and what is good science. The decision making 
process needs to analyse separately health opportunities and risks from ethical and moral considerations. It will 
also be useful that education and dialogue help define human enhancement in comparison to “standard” 
medicine, and thus whether human enhancement should be subject to the same regulation as health. 
(b) Who owns the data and their interpretation? 
Who owns genomic data: the individual, his family, a public health authority, or the company that performs a 
test? Who owns the analysis of aggregated data and their interpretation? 
Related to this issue is the need to develop international guidelines for benefit sharing with developing 
countries, as was done in other fields. People in developing countries must also benefit from and access to 
precision medicine. 
 (c) How to balance privacy and confidentiality with the need for data sharing? 
The question of the right balance between individual rights/health and public concerns/health is highly sensitive 
and its resolution will be determinant for the future of precision medicine, specifically in national policies and 
regulations. Decisions about how genetic information may be collected, stored and used, and by whom, will 
determine how both medicine and research will be able to benefit from the digitalization of health-related data. 
Regulators, industry and patients can work together to establish a clear link between personal and public health 
benefits. If some individuals benefit from early precision medicine, they also, at the same time, contribute to 
enriching the data bases that are needed to develop precision medicine on a larger scale. The collection and 
sharing of personal data benefit the whole, which in turns contributes to better individual treatments. Although 
the debate is ongoing US public opinion on data sharing may be shifting toward openness10.Sensible plans for 
data sharing must be encouraged, while guaranteeing stringent privacy protection safeguards, and clear bans to 
use information against the will of an individual.  
There is ongoing discussion about the value and practicalities of subject informed consent and data 
anonymization in the era of genomic medicine, where individual informed consent impacts relatives, and where 
data anonymization is not absolute.  
 (d) How to react to obvious and dangerous misuse of data? 
In order to develop the necessary trust, there must be criminal penalties for misuse of data11 .Regulatory 
authorities should have emergency regulations in place for dealing with serious misuse of data and in general 
misbehavior on the part of any actor, with regards to fair, ethical and acceptable behaviour. These are similar to 
contingency planning for crisis management. They are needed to create trust between industry, governments 
and society. 
  
                                                          
10 http://www.nature.com/news/giant-study-poses-dna-data-sharing-dilemma-1.18275  
11 Nuffield Council on Bioethics 
28-29 August 2015 IRGC workshop highlights – precision medicine risk governance 
9 
 
(e) How to implement adaptive governance of ownership, collection and use of human genetic information for the 
purpose of developing precision medicine? 
The current development of precision medicine strongly suggests that adaptive governance and regulation will 
be needed. So called “Adaptive Regulation” addresses the following questions: 
 How to make laws today that will be valid in the future, considering for example evolving views about 
privacy? 
 How can the design of policies and regulations accommodate the necessary flexibility, in a way that 
does not induce too much uncertainty to research, industry and society?   
 What are the legal options that are robust to technological change and foster innovation? 
 
 
 
5. Recommendation: Adaptive Regulation 
 
Adaptive Regulation is a form of regulation that integrates several elements: determination of an objective and 
expected achievement, monitoring, planned regular review to provide feedback, adaptation of the regulation to 
improve performance with regard to the initial objective. This provides the necessary flexibility to adapt to 
changing scientific knowledge, new technology, changing context conditions including changes in social values 
and perception of risks and opportunities. This also provides a planning, in order to address the risk of regulatory 
uncertainty. 
Getting regulators comfortable with an adaptive framework with built-in reviews and willingness to be wrong 
and change course enables to reconcile innovation and risk management. 
In the case of precision medicine, the following elements could be included in the monitoring, because they will 
determine how efficacy, safety and cost-efficiency of precision medicine can be improved and thus encouraged 
by regulatory bodies: 
 Linking genetic data and medical records: what progress is made in how genomic data is aligned with 
phenotypic data and medical records? How does this generate improvements in therapies? 
 Performance and efficacy: How does the efficacy compare with conventional medicine? 
 Surveillance of industry and research malpractices, misuse of data: does the number of cases reported to 
health and regulatory authorities increase or decrease? 
 Surveillance of discriminative access to precision medicine (equal access to health), benefit sharing and 
other principles: Does the number of patients treated with gene therapies increase? Algorithms are 
increasingly used to make eligibility decisions. Those must be carefully monitored for potential 
discriminatory outcomes for disadvantaged groups12. 
 Progress towards accountable systems: are automated and continuous auditing systems in place, that 
are able to detect violations of privacy policies and to punish violators improving? 13 
 In the licencing process, elements that can be adaptive include: the treatment eligible population, the 
level of constraint on prescribing, the tightness of surveillance, and the price. 
We propose that these recommendations are refined and compared with those of established authorities and 
report such as the Nuffield Council on Bioethics, the Global Alliance for Genomics and Health, or the US Precision 
Medicine Initiative. 
 
 
  
                                                          
12 Big Data: Seizing Opportunities, Preserving Values, Executive Office of the President, US White House, May 2014 
13 See note 12, page 42 
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Appendix: workshop agenda, references and panelists 
 
OWNERSHIP, COLLECTION AND USE OF GENETIC INFORMATION FOR PRECISION MEDICINE  
A workshop jointly organised by Tsinghua University,  
Massachusetts Institute of Technology (MIT), Swiss Federal Institute of Technology (EPFL),  
and International Risk Governance Council (IRGC) 
with support from Center for Industrial Development and Environmental Governance(CIDEG),  
Tsinghua University 
28-29 August 2015, Tsinghua University, Beijing, P.R. China 
 
PREMISES AND GOALS 
In the context of the tremendous enthusiasm for precision medicine in China and elsewhere, the organisers of 
the workshop wish to discuss governance and regulatory issues related to the development of precision 
medicine in the world. Are there gaps between research, policy initiatives, regulation and practice that require 
attention from policymakers and regulators? Can innovative, effective and realistic governance 
recommendations be developed? 
This workshop will thus discuss adaptive risk management in precision medicines with emphasis on issues 
associated with the collection and uses of genetic data for medical purposes. 
 Applications treated will include variants of precision medicine, from targeting traditional 
therapeutics on genetically defined treatment groups to revolutionary gene therapies and 
regenerative medicines. 
 Effective access to and utilization of genotypic data, in combination with phenotypic data and 
health records, is central to the development of all variants of precision medicine. Yet problems 
of data access and analysis are too often treated in isolation from drug development, licensing 
and use. 
 This workshop will bring together developers of precision medicines, experts on the regulation of 
benefits and risks of pharmaceuticals, and specialists in intellectual property rights, patient 
consent, and cybersecurity and data protection. 
 
The workshop is directed at the following goals: 
 Goal 1: To identify risk governance and regulatory issues in the development of precision 
medicines, with attention to the role of genomic data in providing evidence on the safety, 
efficacy and effectiveness of novel therapeutics under conditions of uncertainty. 
 Goal 2: To describe and assess commonalities and differences in how China, India, the US and 
Europe have regulated precision medicines and managed access and use of genomic data, in the 
context of the high priority assigned to development of precision medicines by China, India and 
OECD nations. 
 Goal 3: To identify potential national and international policy initiatives and to specify associated 
academic research agendas with the end of fostering more effective adaptive regulation of 
benefits and risks of precision medicines and genomic data access and use. 
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AGENDA 
Chair: Prof. XUE Lan 
WELCOME, INTRODUCTIONS AND OVERVIEW 
9:00-9:30 FRIDAY 28 AUGUST 
 XUE Lan, School of Policy and Management, Tsinghua University 
 Kenneth OYE, Center for Biomedical Innovation and Program on Emerging Technologies, MIT 
 Gerard ESCHER, EPFL 
 Marie-Valentine FLORIN, IRGC 
 
SESSION 1: SCIENTIFIC AND TECHNICAL LANDSCAPE 
9:30-12:00 FRIDAY 28 AUGUST 
Goal: To identify risk and benefit governance issues in the development of precision medicines, with 
attention to the role of genomic data in providing evidence on the safety, efficacy and effectiveness of 
novel therapeutics under conditions of uncertainty. 
Themes and Questions: This session will provide a technical foundation for discussion of variants of 
precision medicines and genomic data, with attention to the current state of the art and to future 
developments. 
 What is the current state of the art of precision targeting of conventional therapeutics, of gene 
therapies and of regenerative medicines? 
 How is genomic data currently being collected, curated, stored and analysed for drug development 
and regulatory purposes? 
 How is genomic data currently being aligned with phenotypic data and medical records for these 
purposes? 
 Over the next decade, how will the state of the art on precision medicines, including gene therapies 
and regenerative medicines be likely to change? 
 How will economic and business incentives for data collection and management and the development 
of precision medicines change? 
 How do answers to the questions above differ for China, India, the US and the EU? 
 
Panelists:  
 Jacques FELLAY, EPFL School of Life Sciences and Swiss Institute of Bioinformatics 
 Jeremy LIM, Oliver Wyman, Singapore 
 Kenneth A. OYE, Center for Biomedical Innovation and Program on Emerging Technologies, MIT 
 Saturn Tian, Geneis BioTech 
 Bart C. WEIMER, Population Health and Reproduction, University of California Davis, BGI @ UC Davis 
 ZENG Changqing, Laboratory of Genomic & Precision Medicine, Chinese Academy of Sciences 
 
SESSION 2: ECONOMIC AND REGULATORY LANDSCAPE 
13:00-16:00 FRIDAY 28 AUGUST 
Session chair: Kenneth OYE, Center for Biomedical Innovation and Program on Emerging Technologies, MIT  
Goal: To describe and assess commonalities and differences in how China, India, the US and Europe have 
regulated precision medicines and access to and use of genomic data, in the context of the role of 
development of precision medicines as a strategic priority within China, India and OECD nations. 
Themes and Questions: This session will review legislative principles, regulatory frameworks and informal 
norms that affect the development of precision medicines and the collection, access and use of human 
genetic information. Briefings and discussion will focus on Chinese, Indian, US and EU differences and 
similarities on: 
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Part 1 Licensing and Ethical Issues  
 Regulatory frameworks for licensing of precision medicines, gene therapies and regenerative 
medicines 
 Formal rules and informal norms governing subject consent to uses of data 
 Ethical challenges to human germline modification and other applications 
Panelists: 
 DONG Xiao (Marissa), Jun He Law Office 
 GUO Zhaozhen, BGI-IRB 
 Krishna RAVI SRINIVAS, Research Information System (RIS) for Developing Countries, New Delhi 
 LI Yingjie, Zhongyou Biotechnology Institute 
 Sirpa SOINI, National Institute for Health and Welfare, Helsinki 
 ZENG Xiaofan, BGI-IRB 
Part 2 Access and Utilization of human genetic data  
 Data standardization and curation 
 Intellectual property rights and data ownership 
 Data protection, privacy and security 
Panelists: 
 Arti RAI, Duke University School of Law 
 Daniel WEITZNER, CSAIL Decentralized Information Group, MIT 
 QI Ming, School of Medicine and Watson genomics institute, Zhejiang University 
 YU Hanzhi, School of Public Policy and Management, Tsinghua University 
 
SESSION 3: FUTURE POLICY INITIATIVES AND RESEARCH NEEDS 
09:00-12:00 SATURDAY 29 AUGUST 
Goal: To identify emerging short falls in potential national and international policy initiatives and to specify 
associated academic research agendas, with the end of fostering more effective adaptive regulation of 
benefits and risks of precision medicines and genomic data access and use. 
Themes and Questions: This session will focus on assessing the implications of regulatory differences and 
on recommending regulatory reforms and research agendas. 
 How will existing cross-national and interregional differences in the regulation of precision medicines 
and in the regulation of access to and uses of genetic information affect the location and pace of 
development of precision medicines? Are the rules of the game transparent to researchers, industry 
and patients? 
 Are regulatory differences likely to persist or converge? Will differences provide distinct national 
competitive advantages? Conversely, will differences limit data sharing and collaboration to the 
detriment of technical advance? Are there common principles for regulation of genomic data and 
precision medicines that could serve as a core for international cooperation? 
 How might planned adaptive regulations be designed to deal with changing scientific developments, 
evolving understandings of risks and benefits, and shifting norms/values on appropriate uses of 
genomic data and applications of precision medicines? What provisions for regulatory revision may be 
identified? What research priorities might be identified to reduce critical policy relevant sources of 
uncertainty? What sources of support for and opposition to an adaptive regulatory approach may be 
anticipated? 
 
Panelists: 
 CHEN Tao, Thermo-Fisher Scientific China 
 David GU, Shanghai Quanment High Tec Company 
 Gerard ESCHER, EPFL Lausanne 
 Kenneth OYE, Center for Biomedical Innovation and Program on Emerging Technologies, MIT 
 Kevin WALMSLEY, GU David, Shanghai Quanment High Tec Company 
 QI Ming, School of Medicine and Watson genomics institute, Zhejiang University 
 XUE Lan, School of Policy and Management, Tsinghua University 
 ZENG Changqing, Laboratory of Genomic & Precision Medicine, Chinese Academy of Sciences  
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